In addition, the N-803 from Anktiva, a modified IL-15-based fusion protein (IL-15Rα-Fc), functions as an immunostimulatory agent that drives the expansion and activation of NK cells and CD8+ T lymphocytes (209), is being evaluated in progressive or recurrent glioblastoma (NCT06061809). This evidence concerns the gene CD8A and glioblastoma.